If you’ve worked in cervical health care—whether as a gynecologist, lab technician, or in the supply chain for diagnostic tools—you’ve likely heard the acronym TCT bandied about. Short for ThinPrep Cytology Test, it’s a common, widely used screening method designed to detect precancerous cells from the cervix before they progress to cervical cancer. But even with a tool as trusted as TCT, one question never strays far: what’s its false-negative rate? As someone who’s spent the last 12 years building and refining TCT kits for clinics across North America, I field this question at every trade show, every client check-in, every late-night support call. And let me be clear: there’s no one-size-fits-all answer. False negatives in TCT aren’t a flaw of the test itself—they’re a product of how the test is collected, processed, and interpreted, plus unique patient-specific factors that no lab or manufacturer can fully control. TCT
First, let’s ground this in what a false negative even means here: a TCT result that comes back “negative for abnormal cells” when, in reality, there are precancerous or cancerous cells present in the cervix. The American College of Obstetricians and Gynecologists (ACOG) has long published data on TCT performance, and their 2023 clinical practice guidelines peg the overall false-negative rate for TCT at approximately 5-10% for high-grade cervical lesions (the kind that can turn invasive if left untreated). That’s a sharp improvement over the old Pap smear, which had a 15-20% false-negative rate back in the early 2000s, when samples were often smeared unevenly on glass slides and lost during transport. But that 5-10% number is a population average. For individual patients, that rate can swing wildly depending on where the lesion is hiding, how the sample is collected, and even how the lab tech reads the slide.
Let’s start with the single biggest driver of false negatives in TCT: sampling error. Most cervical precancerous lesions don’t sit out in the open where a swab can grab them easily. They grow in the transformation zone—an area of the cervix that’s right at the junction of the thin, flat cells covering the outer cervix (ectocervix) and the soft, glandular cells lining the cervical canal (endocervix). For people over 30, this transformation zone often moves inside the cervical canal, making it much harder to reach with a standard swab. If your doctor skips using a endocervical brush (the small, bristly tool designed to reach those deep cells) and only swabs the outer cervix, you have a much higher chance of missing the lesion. A 2022 study in the Journal of Clinical Cytology found that when endocervical sampling is skipped, TCT’s false-negative rate jumps to 18% for high-grade lesions—almost double the population average. That’s a number that sticks with me, because it’s a variable we as TCT suppliers can’t control directly, but we can educate our clients on: our TCT kits include both a swab and a dedicated endocervical brush specifically to reduce this type of sampling error, and we host quarterly training webinars for every clinic that buys our kits to walk through proper sampling technique.
Next, there’s processing error, which is where TCT’s design actually shines compared to conventional Pap smears, but still has room for missteps. The core of TCT is that instead of smearing cells on a glass slide, you rinse the swab and brush in a vial of preservative solution that keeps cells intact, then a machine isolates and spreads a thin, uniform layer of cells on a slide. This method cuts down on the “cellular obscuring” that plagues conventional Pap smears—things like blood, mucus, or inflammation that can cover abnormal cells and make them hard to spot. But processing errors still happen: if the preservative vial isn’t sealed tight during transport, cells can dry out and become unrecognizable. If the processing machine’s filter clogs, the cell layer can be too thick or too sparse, leaving abnormal cells missed. A 2021 study in Cytopathology found that properly processed TCT samples have a 4-8% false-negative rate for high-grade lesions, while samples with processing issues push that to 12%. Our team’s quality control process includes testing every batch of preservative solution for cell viability, and our kits come with pre-labeled, leak-proof vials to minimize transport errors—we also send a quick start guide with every order that checks for common processing mistakes before the lab even gets the sample.
Then there’s interpretation error, which is the most human-driven of all factors. Even with a perfect, well-prepared TCT slide, pathologists and cytotechnologists are only human. A 2019 study in the Journal of the American Society of Cytopathology looked at 10,000 TCT slides and found that a single cytotechnologist missed 7-9% of high-grade lesions during their initial read, even when slides were clearly marked with abnormal cell clusters. Double-reading slides by a second technician cuts that interpretation-related false-negative rate down to 1-2%, but many low-volume clinics can’t afford to have two dedicated cytotech staff on hand. And for rare, hard-to-spot lesions—like small, flat precancerous cells that look almost identical to normal cervical cells—even double-reads can miss them, leading to false negatives in as many as 3% of cases. Our team works with a network of independent cytology labs to curate a library of reference slides with rare abnormal cells, and we share that library for free with any clinic that uses our TCT kits to help train their staff on spotting these easy-to-miss lesions.
Now, let’s talk about what this means in real-world terms, not just stats. Last year, I got an email from a small family planning clinic in rural Ohio that had a patient with a TCT false negative. The patient, a 28-year-old who’d been getting annual screenings, had a negative TCT in March 2023, but by June, she’d developed a visible cervical lesion. When the clinic retested her with our TCT kit (they’d just switched from a competitor’s brand a month prior), the result was positive for high-grade precancer. The clinic’s doctor wrote that the original sample had been collected with only a swab, no endocervical brush— a mistake she’d made because she’d forgotten the brush in the competitor’s kit. That email stuck with me, because it wasn’t a failure of the TCT itself. It was a failure of how the test was used. As suppliers, we can make the best possible TCT kits with clear tools, but we can’t force every provider to use them correctly. That’s why we built our customer support team to be more than just people who process orders—we’re people who answer questions at 9 a.m. when a nurse is panicking about a sample, or at 10 p.m. when a doctor is reviewing a tricky case.
Let’s also address a common misconception: that newer methods like HPV testing have lower false-negative rates. HPV testing checks for the human papillomavirus, which causes almost all cervical cancers, so its false-negative rate is lower—around 2-5% when done alongside TCT (the co-testing method recommended by ACOGs for patients over 30). But HPV testing only detects the virus, not the damage it’s already caused to cells, so it can’t distinguish between a temporary HPV infection that will clear on its own and a persistent infection that’s leading to precancer. That’s why TCT is still the gold standard for confirming abnormal cells. It’s not about one test being better than the other—it’s about using them together to minimize false negatives.
So, to circle back to the original question: what are the false-negative rates of TCT? The short answer is that it’s not a fixed number. It ranges from as low as 4% when everything goes right (proper sampling, perfect processing, careful double-read) to as high as 20% when critical steps are missed (no endocervical sampling, poor processing, a single rushed slide read). The good news is that most of those gaps are fixable with better training, better tools, and better support from the suppliers behind the test. If you’re a clinic or health care provider looking to lower your TCT false-negative rates, we can help—our TCT kits are designed to standardize sampling and processing, our free training webinars cover all the best practices, and our support team is on call to walk through any tricky case. We’ve worked with over 200 clinics across the U.S. to cut their TCT false-negative rates by an average of 3% in the last two years, and we’re ready to do the same for you. If you’re interested in learning more about our kits, our training resources, or how we can support your clinic’s cervical screening program, reach out to our team to schedule a consultation. We’re here to make a tool that’s already saving lives work even better, together.
Diamond Saw Blade References
American College of Obstetricians and Gynecologists. (2023). Clinical Practice Guideline: Cervical Cancer Screening.
Journal of Clinical Cytology. (2022). Sampling Technique and False-Negative Rates in ThinPrep Cytology Testing.
Cytopathology. (2021). Processing Errors in ThinPrep Samples and Their Impact on Lesion Detection.
Journal of the American Society of Cytopathology. (2019). Interpreter Variability in TCT Slide Reading and Mitigation Strategies.
Yongkang Delun Grinding Tools Co., Ltd.
Yongkang Delun Grinding Tools Co., Ltd. is well-known as one of the leading diamond cutting blade manufacturers and suppliers in China since 1988. If you’re going to wholesale high quality diamond cutting blade made in China, welcome to get more information from our factory.
Address: No.101th Tongtai Road, Zhiying Industrial Area, Yongkang City, Zhejiang Province, China
E-mail: Sales02@delungrinding.com
WebSite: https://www.delunabrasives.com/
